APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-24

Price

$134.79

+0.03%

This is the 2026-08-24 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score11.0Top Tier

Signals6/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

The price action of Apogee Therapeutics (APGE) is entirely dictated by its pending acquisition by AbbVie for $135.11 per share in cash. The stock's exceptionally low 1.6% annualized volatility and technical signals like QUIET_STORM perfectly reflect a classic merger arbitrage setup where shares are pinned just below the buyout price. In the current RISK_ON macro regime characterized by structural liquidity and tight credit spreads, institutional investors are comfortably stepping in to capture the remaining yield. This is confirmed by recent filings showing massive accumulations by funds like BlackRock, signaling high conviction that the deal will close without regulatory friction.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUE

Key Takeaways

M&A Pinning: APGE is trading at $134.79, representing a tight and stable merger arbitrage spread against AbbVie's $135.11 all-cash acquisition offer.
Institutional Absorption: Recent filings reveal major funds like BlackRock taking significant $730M+ positions, absorbing any retail selling to capture the remaining spread.
Low-Volatility Drift: The PERFECT_STACK and STEADY_CLIMB signals reflect a derisked asset waiting for deal closure, rendering broader market regime fluctuations irrelevant.

← Back to 2026-08-24 View Full APGE History →Yahoo Finance &nearr;